Daily Stock List
Remedent, Inc. (REMI)
FeedBlitz, Stock Guru, and SmallCapVoice reported previously on Remedent, Inc. (REMI), and today we choose to highlight the Company, here at the QauliotyStocks Daily Newsletter.
Remedent, Inc. serves consumers and the dental community with unique porcelain veneer, teeth whitening, and sensitivity and oral hygiene products. The Company creates state-of- the-art dental technologies and marketing concepts. Products include GlamSmile Veneers, GlamSmile Whitening, Smile Consultancy, First Fit, as well as others. Remedent's shares trade on the OTCQB; the Company has their headquarters in Gent, Belgium.
Remedent's products have recognition globally for their technological superiority and unique ease-of-application. The Company manufactures, as well as markets and distributes their line of products and concepts to more than 25 countries around the world.
For Business-to-Consumer, Remedent began with a B2C approach based on the Smile Consultancy Concept. GlamSmile's Smile Consultancy Program goal is to help consumers to realize their dream of a beautiful smile through consulting by a Smile Coach. While the concept still works with dentists, the complete sales cycle is taken over by Remedent. Their approach to market the Smile is predominantly internet based.
As pertains to Business-to-Business products, Remedent developed and marketed whitening products in combination with the high-speed curing lamp Remecure. Remewhite Formulation+ by GlamSmile was the first available in-office power whitening gel featuring Remedent's proprietary CRM-Technology. Remedent created and sells GlamSmile White Boost through dentists for home use. It is an oxygen-induced whitening system.
Remedent's leading smile improvement system, GlamSmile, revolutionizes the traditional one-at-a-time method of applying porcelain dental veneers. GlamSmile involves a proprietary veneer fabrication technique and a patented single-motion veneer placement tray that are both guided by a proprietary computer imaging, design, and digital preview system. The tray delivery system lets dentists expertly seat 10 ultra-thin, custom veneers in less than an hour while preserving tooth structure.
Moreover, the Company developed "FirstFit". It features a patent-pending system for the creation and placement of dental crowns and bridges. The FirstFit system requires no temporary placements, creates less mouth trauma, and takes fewer office visits to complete.
Remedent has a partnership in GlamSmile Beijing. The Beijing GlamSmile Clinic is a place for consumers wanting to change their smile. The Clinic offers an array of cosmetic dental procedures including GlamSmile veneers, whitening, invisible braces, crowns, bridges, and more. The GlamSmile Laboratory, founded in January 2009, designs and produces veneers for international delivery.
Last month, Remedent announced their exclusive agreement with Biotech Medical Aesthetic SAS for distributing their River 8 veneers globally. River 8 is an innovative, painless, and affordable porcelain veneer solution for discolored, damaged, stained or misaligned teeth. It will be produced by Remedent and distributed worldwide by Biotech International. Both partners have agreed on a renewable 5 years contract with a first order of 1 million Euros (1,35 million USD).
Remedent, Inc. (REMI), closed Friday's trading session at $0.14, up 33.33%, on 75,000 volume. The average volume for the last 60 days is 24,867 and the stock's 52-week low/high is $0.09/$0.50.
TruLan Resources, Inc. (TLAN)
Today we are reporting on TruLan Resources, Inc. (TLAN), here at the QualityStocks Daily Newsletter.
Based in Henderson, Nevada, TruLan Resources, Inc. is an exploration and mining development company. The Company's corporate mission is the exploration and development of mining properties whose economic potential is considered to be extensive, while requiring minimal infrastructure and operational costs, which can be advanced in an environmentally responsible manner. TruLan has a focus on Gold, Silver, and Platinum Group Metals (PGM) projects in North and South America. The Company's shares trade on the OTC Pink Current Information.
The commitment of the TruLan team is to the acquisition of properties that have previously undergone significant exploration and work programs, and where a comprehensive data package exists. The Company's Eureka Placer Claim is situated on Eureka Creek in California's Sierra City Mining District. It is at the southern portion of a major belt of gold mineralization that extends to the northern district, Johnsville Mining District, located in Plumas County. The principal Tertiary channel deposits are at Eureka, Craig's Flat, Morristown, and Monte Cristo, the most extensive being at Eureka. The Eureka placer mining claim is on Eureka Creek, directly downstream from the Eureka Diggings hydraulic mine site. The claim encompasses ¾'s of a mile of Eureka Creek.
Yesterday, TruLan Resources announced that they entered into a definitive agreement to acquire a 100 percent interest in the IGP Iron Gold Platinum Project in the IV Region – Region de Coquimbo – of Chile. The relatively small region has a long history of mining; a number of operations are presently in production. This includes the Los Pelambres Deposit, which is the world's fifth largest copper mine.
The IGP Project totals 885 Hectares (2,186 Acres) of widespread mineralization and ore bodies that contain high grades of Iron, Gold, Platinum and high value industrial metals. Eight known deposits in close proximity have undergone testing to the point where an Indicated Ore resource has been delineated. Under the definitive agreement, TruLan Resources will acquire four ore bodies with an aggregate Indicated Reserve of greater than 247 Million Metric Tons.
Today, TruLan Resources reported that, following an economic review of the recently acquired IGP Project in Chile, there are two acknowledged sources of revenue that they can realize from the Project. Extraction and processing of the ore is considered straightforward in nature and requires the construction of technologically specific but well understood equipment.
TruLan's intention is to develop an exploration work program to test the IGP bedrock. The Company plans to begin this work as soon as possible. The development plan and construction of the processing facility is a primary focus; Trulan expects to have an engineering report within the second quarter.
TruLan Resources, Inc. (TLAN), closed Friday's trading session at $0.12, down 4.00%, on 465,288 volume with 84 trades. The stock's 52-week low/high is $0.09/$2.10.
Northern Gold Mining, Inc. (NGM.V)
We are reporting on Northern Gold Mining, Inc. (NGM.V) today, here at the QualityStocks Daily Newsletter.
Headquartered in Toronto, Ontario, Northern Gold Mining, Inc. is a junior resource company. They concentrate on the discovery and development of high value mineral deposits in the proven mining camps of Kirkland Lake and Timmins in northeastern Ontario. Northern Gold Mining's objective is to become an efficient, low cost regional gold producer. In February 2013, the Company announced that they were recently recognized as a TSX Venture 50® Company in 2013, as one of ten top ranked companies in the Mining Sector listed on the TSX Venture Exchange.
Northern Gold Mining is focusing on outlining two gold deposits at an advanced stage of exploration on their 100 percent owned Garrison Gold Property. Recently, they acquired the Buffonta Property, only 4 km southwest. In addition to the Jonpol and Garrcon gold deposits, the Garrison Property hosts several other gold mineralized showings. This includes the less advanced 903 gold mineralized area. Northern Gold has historical mining infrastructure at the Jonpol and Garrcon Deposits. The Company is beginning exploration of the Buffonta Property, and they continue to expand their land holdings in the region.
At the end of November 2012, Northern Gold Mining announced that they entered into a definitive option agreement with various property interest holders including Tiger Gold Exploration Corp. Northern Gold has been granted the exclusive right to earn up to a 100 percent interest in certain mining claims and leases located in Harker, Holloway, Elliott, Garrison, Thackeray, Marriott and Tannahill Townships, Ontario.
The Property consists of 18 patented mining claims, 806 unpatented mining claims units and 2 leases consisting of an aggregate of 13 claim units and extends across approximately 14,240 hectares. Pursuant to the terms of the Option Agreement, Northern Gold Mining can acquire an initial 80 percent interest in the Property.
At the end of January 2013, Northern Gold Mining announced that they entered into two mining claim acquisition agreements. Northern Gold can acquire a 100 percent interest in a significant mining claim located in Garrison Township, Ontario (the Garrison Claim) and an 80 percent interest in one lease (CLM352) consisting of a block of 11 mining claims located in Harker Township, Ontario. The acquisition of the Garrison Claim and CLM352 increases Northern Gold Mining's expanding land package to approximately 50,175 acres in the Larder Lake Mining District.
On February 7, 2013, Northern Gold Mining reported that they completed the acquisition of a 100 percent interest in Victory Gold Mines, Inc. (as previously announced on December 12, 2012). With the terms of an amalgamation agreement dated December 12, 2012 between Northern Gold, Victory Gold and a wholly owned subsidiary of Northern Gold (Subco), Subco and Victory Gold have amalgamated to form a wholly owned subsidiary of Northern Gold.
Northern Gold Mining, Inc. (NGM.V), closed Friday's trading session at $0.17, down 5.56%, on 203,700 volume. The stock's 52-week low/high is $0.18/$0.45.
China Ceetop.com, Inc. (CTOP)
Today we are reporting on China Ceetop.com, Inc. (CTOP), here at the QualityStocks Daily Newsletter.
An Oregon-registered corporation, China Ceetop.com, Inc. is a leading Business-to-Consumer (B2C) e-commerce company. They own and operate the online platform: www.ceetop.com. The Company's dedication is to offering a premier online shopping experience, fast delivery, as well as exemplary customer service. China Ceetop.com lists on the OTC Markets' OTCQB. The Company has their corporate headquarters in Shenzhen, the People's Republic of China. They additionally maintain an operating office located in Hangzhou, China.
China Ceetop.com sells computers/communications/consumer products online. They also provide a trading information platform for buyers and sellers as software as a service (SaaS). The Company owns and operates the aforementioned ceetop.com, which is an online platform that sells digital products, home appliances, kitchen appliances, personal care products, as well as lifestyle products.
The Company's website adopts an initiative B2C mode. They connect directly with high-end channels in the 3C industry (Computers/Communications/Consumer). Therefore, they lower the cost in a number of aspects. In the meantime, China Ceetop.com substantially reduces their delivery expense via close cooperation with leading third party logistic companies. All of these contribute to the Company's pricing system. China Ceetop.com has expanded and they have become one of the top domestic and global online stores for 3C products.
For the three months ended September 30, 2012 and 2011, China Ceetop.com's net sales were $1,244,458 and $3,214,882 respectively, a decrease of 61 percent. For the nine months, ended September 30, 2012, sales were $3,888,116, compared to $10,402,375 at September 30, 2011, a decrease of 63 percent.
This decrease in net sales was because of high competition in online shopping. Therefore, the Company began the transition from online retail sales to focus more on sales to a relatively smaller number of distributors.
The Company's net loss was $151,278 and $468,306, and $663,757 and $1,197,045, for the three and nine months ended September 30, 2012 and 2011, respectively. The three-month decrease of 68 percent and nine-month decrease of 45 percent resulted primarily from decreased sales over the respective period.
China Ceetop.com, Inc. (CTOP), closed Friday's trading session at $0.363, up 1,715.00%. The average volume for the last 60 days is 80 and the stock's 52-week low/high is $0.002/$2.00.
Huabao International Holdings Ltd. (HUABF)
Today we are reporting on Huabao International Holdings Ltd. (HUABF), here at the QualityStocks Daily Newsletter.
Huabao International Holdings Ltd. is a market leader in China's flavor and fragrance industry. Huabao International takes on leadership roles in various industry associations. These include the Deputy Director of CAFFCI, Deputy Director of China Food Additives & Ingredients Association, and Chairman of Shanghai Food Additive Industry Association.
An investment holding company, Huabao International Holdings has offices in Wanchai, Hong Kong and Shenzhen, China. The Company's shares trade on the OTC Markets' OTC Pink Current Information.
Huabao International Holdings has an integrated core value chain, established upstream raw material extraction bases in Botswana, southern Africa, Shandong, Jiangsu, Yunnan and Hunan, as well as production bases in Shanghai, Yunnan, Guangdong, Jiangsu, Fujian, and Hong Kong, and elsewhere.
Furthermore, the Company has established an R&D center in Holzminden, Germany, a State recognized technical center in Shanghai, and R&D departments in Guangdong, Yunnan, as well as Fujian. In fact, the technical center of Huabao Shanghai (a wholly owned subsidiary of the Company) is currently the only State-recognized technical centre in the People's Republic of China's (PRC's) flavor and fragrances industry.
Huabao International researches, develops, manufactures, and sells tobacco, and food flavors and fragrances in the PRC. The Company involves in the technical research and development, production, distribution, import, and export of flavors and fragrances, as well as related services; and the manufacture and sale of tobacco flavors and fragrances. In addition, they engage in the manufacture, trade, and sale of fine chemicals; the production and sale of natural extracts; and the research and development (R&D), manufacture, and sale of reconstituted tobacco leaves (RTL).
Flavor products are mixtures of specific aromas and flavors manufactured through blending different natural and synthetic aromatic materials. The Company has two China registered trademarks that have significant recognition in Shanghai. "Kongque" is a long established food flavors brand in the PRC. "Xideng" is a renowned brand name of tobacco flavors in the PRC that has the largest market share in China.
Huabao International Holdings Ltd. (HUABF), closed Friday's trading session at $0.490348, even for the day. The average volume for the last 60 days is 370 and the stock's 52-week low/high is $0.01/$0.80.
Fjordland Exploration, Inc. (FEX.V)
We are highlighting Fjordland Exploration, Inc. (FEX.V), here at the QualityStocks Daily Newsletter.
Fjordland Exploration, Inc. is a mineral exploration company whose shares trade on the TSX Venture Exchange. The Company focuses on the discovery of gold, copper and molybdenum deposits in British Columbia (BC). Currently, Fjordland has a portfolio with 25 properties. Incorporated in 1996, Fjordland Exploration has their headquarters in Vancouver, BC.
The Company has a 100 percent interest in 5 properties known as "Tak" totaling 45,828 ha in the Woodjam area of central BC. Fjordland Exploration and Serengeti Resources, Inc. (SIR.V) are 34.8 percent/65.2 percent partners exploring 11 properties (QUEST Project) totaling 49,753 ha in the Quesnel Terrane north of Woodjam for precious and base metals.
Six of the QUEST properties (totaling 27,690 ha) have been optioned to Xstrata Copper. The QUEST JV owns 100 percent of the remaining 5 properties totaling 22,064 ha. Fjordland has a 100 percent interest in 2 properties totaling 17,657 ha in the Iron Range in southeastern BC. The Company has an option to acquire a 100 percent interest in the Dillard and Dill copper and gold properties, north of Princeton.
Yesterday, Serengeti Resources and Fjordland Exploration announced that they consolidated their adjoining Mil (SIR-65 percent/ Fjordland -35 percent) and Milligan South (100 percent Fjordland) properties into a single project (50/50 JV), "Milligan West". This is by way of an amendment to the previous QUEST Joint Venture agreement, dated February 21, 2008 between Serengeti and Fjordland.
The Property consists of 15,736 hectares (ha); it is approximately 160 kilometers northwest of Prince George, BC. The Property adjoins the western boundary of Thompson Creek Metals Ltd.'s Mt. Milligan copper-gold project, scheduled to begin production later this year, following a capital investment estimated at $1.5 billion.
Serengeti Resources and Fjordland Exploration are presently collecting all previous exploration data for the Mil and Milligan South properties into a single database for the Property. With current market conditions, they've elected to look for a Joint Venture partner to advance the consolidated project.
Fjordland Exploration, Inc. (FEX.V), closed Friday's trading session at $0.015, even for the day, on 17,200 volume. The stock's 52-week low/high is $0.01/$0.08.
TexStar Oil Corp. (TEXS)
We are highlighting TexStar Oil Corp. (TEXS) today, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, TexStar Oil Corp. applies state-of-the-art petroleum and natural gas exploration and extraction technology to the development of oil and natural gas projects. The Company's focus areas include Texas, Oklahoma and Louisiana. Their exploration activities are focusing on adding profit generating production to existing core areas and developing potential new core areas. TexStar Oil is based in Dallas, Texas.
The Company's production operations supply liquid hydrocarbons and natural gas to the growing global energy markets. The current focus of worldwide production operations are in North America. TexStar's main objective is to increase the value of acquired properties via a combination of exploitation, drilling and proven engineering extraction practices. The Company's most significant emphasis is on CO2 tertiary recovery operations.
TexStar Oil's business strategy includes acquiring oil and gas properties that give the Company a majority working interest (WI) and operational control or where they believe they can ultimately obtain it. Their strategy also includes maximizing the value of their properties through increasing production and reserves while controlling cost.
Their strategy involves maintaining a highly competitive team of experienced and incentivized personnel and engineers. In addition, TexStar's strategy involves remaining focused in specific regions where the Company has a competitive advantage because of their ever-expanding infrastructure, or where they believe they can ultimately obtain it.
Furthermore, the Company's business strategy involves acquiring properties where they believe additional value can be created by way of secondary and tertiary recovery operations and a combination of other exploitation, development, exploration and marketing techniques.
Mr. Jeff Jacobson is the President of TexStar Oil. Mr. Jacobson has more than 20 years experience in International Business development and relationship building. As the Company's President, he oversees all business development and expansion. He started his international career in 1992 while helping Nuskin International develop and launch the Japan market.
TexStar Oil Corp. (TEXS), closed Friday's trading session at $1.20, up 60.00%, on 1,101 volume with 7 trades. The average volume for the last 60 days is 145 and the stock's 52-week low/high is $0.50/$2,500.00.
Quantum International Corp. (QUAN)
OTC Stock Pick and Best Microcap Stock reported yesterday on Quantum International Corp. (QUAN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Pink Current Information, Quantum International Corp. is a robotics innovation company. They are working to commercialize the next generation of sophisticated, automated technology. The Company is positioning themselves to develop, deliver and market the most cutting-edge innovations in robotics. This is to take advantage of the global demand for the precision, speed, and cost-effectiveness these technologies offer. Incorporated in 2001, Quantum International has their headquarters in Houston, Texas.
The Company is seeking out leading-edge developers of advanced robotics technologies for potential acquisition or partnership. Quantum International's objective is to market and develop these technologies to meet the aforementioned growing global demand. The Company is moving aggressively to become a real player in the international robotics market. This market is forecast to grow in value to approximately $21.4 billion by 2014.
Yesterday, Quantum International reported that the feature-packed iPad accessory undergoing development by the Company is moving from the drawing board to the workshop. Engineering started this week to produce a working prototype of the device for testing. Currently, there are more than 117 million iPad owners around the world.
The design of the all-in-one accessory is to give the Apple (AAPL) iPad all of the features of a high-end laptop. This includes peripheral ports, the ability to connect storage devices, an extended battery pack, speakers, a keyboard and more, which are all packed into a stylish, protective case. Quantum has contacted manufacturers in China concerning initiating production of the innovative accessory as soon as a prototype can be produced that meets internal performance targets.
Quantum International Chief Executive Officer, Mr. Robert Federowicz, said, "This accessory is going to increase the iPad's usability far beyond what's currently possible. There's nothing like it in the marketplace today, and we expect it to become the top must-have accessory for every iPad fanatic. We've contracted a reputable, international engineering firm to construct the prototype, and we can’t wait to take it for a test drive."
Quantum International Corp. (QUAN), closed Friday's trading session at $0.125, up 44.01%, on 2,877,729 volume with 383 trades. The average volume for the last 60 days is 206,870 and the stock's 52-week low/high is $0.05/$5.20.
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.64, even for the day, on 52,950 volume, over 19x the 30-day average on 31 trades. The stock’s average daily volume over the past 30 days is 2,695, and its 52-week low/high is $0.06/$3.05.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.104, up 0.97%, on 4,042,415 volume with 204 trades. The stock’s average daily volume over the past 60 days is 4,879,911, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Provide 2013 Business Outlook on March 6, 2013
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
Chairman and CEO of Advaxis Featured in Exclusive SmallCapVoice Interview
The Guitammer Company Inc. (GTMM)
The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.16, even for the day, on 30,000 volume with 6 trades. The stock’s average daily volume over the past 60 days is 15,864, and its 52-week low/high is $0.082/$0.35.
The Guitammer Company Inc. (GTMM) is a leader in low frequency sound products and technology. Its innovative and award winning line of patented ButtKicker-brand low frequency audio transducers let users feel low-frequency sound (bass). ButtKicker brand products are used around the world by leading entertainment and theater companies such as AMC, IMAX and Disney in movie theaters and attractions; by world-famous musicians; in home theaters, simulators and for car audio.
ButtKicker brand products are distributed by Pearl Drums for musicians under the trade name, "Pearl's Throne Thumper by ButtKicker", and factory installed in home theater seating by Palliser Furniture. ButtKicker brand products' patented design makes them musically accurate, powerful and virtually indestructible. The Company is headquartered in Westerville, OH.
The Guitammer Company's newly patented broadcast technology, ButtKicker LIVE! enables the excitement, impact and feeling of sporting events to be broadcast along with the sound and video. ButtKicker LIVE! puts you into the action, whether you're at home or at the event.
ButtKicker Live! technology is available for cable, satellite, fiber optic, IPTV and over-the-air broadcast and has been successfully tested with several major content (sports) providers. ButtKicker(r) and ButtKicker Live!(r) are registered trademarks of The Guitammer Company. Disclaimer
The Guitammer Company Inc. Company Blog
The Guitammer Company Inc. News:
Guitammer Joins Nationwide, North America's Largest Buying and Marketing Organization
Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
Guitammer Third Quarter Revenue More Than Triples To $555,000
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.1725, even with yesterday's close, on 33,162 volume with 41 trades. The stock’s average daily volume over the past 60 days is 168,791, and its 52-week low/high is $0.15/$0.30.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium's ExcellagenŽ Awarded American Podiatric Medical Association Seal of Approval, Company Also Announces Addition of a Regional Distributor for Excellagen
Cardium Announces Presentation at The 2013 Cell & Gene Therapy Forum
Cardium To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
When it comes to the pharmaceutical world, few things are more important than current and future relationships with other companies and organizations. For emerging companies, partnerships are often critical, helping to drive research and build portfolios. On the other hand, future potential relationships, in the form of takeovers or the sale of licensing rights, can represent a company’s primary payoff for all of its hard work. An example of such a payoff is Biogen Idec’s recent agreement to pay Elan Corp. a whopping $3.25 billion for its stake in the multiple sclerosis medicine Tysabri. Flush with the new money, Elan is now able to itself go hunting for possible acquisitions.
None of this is lost on VistaGen Therapeutics, a California-based developer of advanced stem cell technologies designed to provide superior drug testing options for pharmaceutical companies, allowing drug candidates that were previously shelved due to toxicity issues to be economically rescued. The company’s goal is to use the technology to generate a diverse drug pipeline consisting of new, proprietary, small molecule variants (Drug Rescue Variants) of once-promising drug candidates. The market potential is unlimited.
On the research and development side, VistaGen has surrounded itself with a network of successful partnerships, accelerating technological development and also establishing key contacts throughout the industry.
Partnerships with commercial entities include the following:
• Cato Research, a contract research organization, provides regulatory and drug development expertise and also acts as a source of potential drug rescue candidates and collaborations.
• ChanTest provides services that range from early functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process – to a complete set of in vitro GLP service products for cardiac risk assessment.
• NuPotential, LLC, addresses the high-growth cell therapeutics market by developing new systems for evaluating and directing human cell reprogramming.
• Synterys is a medicinal chemistry and collaborative drug discovery provider focused on the needs of virtual and small drug discovery companies.
• TET Systems offers technology that provides efficient, precise, and reversible control over both timing and level of gene expression in eukaryotic cells.
For additional information on these and other partnerships, visit the company’s website at www.VistaGen.com
Recently, SeeThruEquity initiated coverage on International Stem Cell Corp., a development-stage biotechnology company focused on therapeutic, biomedical, and cosmetic products derived from human cell technologies. In particular, ISCO has developed a proprietary technology platform for generating pluripotent human parthenogenetic stem cells (“hpSCs”). The company aims to use its advancements in human stem cell technology to become a leader in regenerative medicine by using cell-based therapies to treat disease.
Like embryonic stem cells, parthenogenetic stem cells have the potential to differentiate into various types of cell types in the human body, yet do not require the use or destruction of a human embryo, avoiding a major source of controversy. In addition, because of the way they are generated, parthenogenetic stem cells carry a duplicate set of human leukocyte antigen genes, which significantly reduces the possibility of the derived cells being rejected by a patient’s immune system. Immune rejection is a major problem with the successful application of stem cell technology, and parthenogenesis largely eliminates it.
SeeThruEquity’s positive initiation report emphasized ISCO’s proprietary parthenogenetic technology, their therapeutic market opportunity, and the supportive advantage represented by their two wholly-owned subsidiaries.
• The report points out that ISCO is initially targeting diseases of the brain, liver, and eye – areas where cell and tissue treatment have proven effective but where there is a short supply of safe and efficacious cells. Specifically, ISCO is developing neuronal cells for use in treatment for Parkinson’s disease, hepatocytes for acute and chronic liver diseases, and corneal cells to treat various degrees of corneal blindness. The company believes this represents a potential market of over $4 billion.
• The report also highlights the importance of ISCO’s proprietary techniques for deriving human parthenogenetic stem cells, stressing that they may provide the company a competitive differentiation versus peers. ISCO has a broad intellectual property portfolio with over 130 patents and licenses across 30 patent families.
• Finally, ISCO has two revenue-generating wholly-owned subsidiaries, Lifeline Skin Care and Lifeline Cell Technology, both of which leverage the company’s human cell culture experience and proprietary stem cell technology platform.
The report concludes the ISCO has a high growth potential over time considering current commercial and future therapeutic applications derived from its proprietary stem cell technology platform.
For additional information, visit www.InternationalStemCell.com
Flexpoint Sensor Systems, the Utah-based developer and supplier of advanced thin-film sensing technology, like their proprietary single-layer Bend Sensor® (which allows for extremely precise, ubiquitous mechanical movement, air flow, water flow, or even vibration sensing), reported entry today into a key partnership that significantly bolsters the company’s assembly, component distribution, manufacturing, and supply-chain logistics capacity.
Well-known, Denver-based, ISO 9001:2008 registered (also ROHS/REACH certified) electronic component distributor and value-added solutions provider, Walker Component Group, will make a powerful strategic ally for FLXT, spring boarding finalization of deals with major companies currently working with Flexpoint, HTK, Intertek, and others on various projects. This deal is a marketing coup that expands FLXT’s manufacturing, assembly, and component acquisition
services footprint enough to resolve the logistical concerns associated with getting the company’s products out the door rapidly and in great number.
The Walker Group has several Fortune 100 clients and has earned a reputation for adept execution of solutions and supply requests, with over 1k clients spanning the upper market echelons and on down into the realm of regional/local firms, who have all come to place ironclad trust in Walker for ready supply of their needs. The leadership Flexpoint has established in innovative engineering and design will really shine now that the company is associated directly with a distinguished and recognizable manufacturing partner like Walker.
CEO of FLXT, Clark Mower, spoke very highly of how this partnership repositions the company in the eyes of groups they deal with on a regular basis. Groups who might get concerned about Flexpoint’s smaller size have their fears assuaged by this partnership, which offers a clear production, purchasing, aggregation, and assembly vector in Walker. Mower also pointed out the stockpiling and warehousing upgrade this deal represents, meaning the company can do bigger trades with higher volumes and at better prices, instead of more piece-meal type jobs.
Customers who are really attracted to FLXT’s incredible sensor technology, but are worried about rolling out a huge deployment in short order, can now rest assured that the firm has the logistical muscle to make it happen. This will satisfy Intertek and users of the HTK Engineering system in particular, who can now forget about worrying over order fulfillment, as the deal presents them with an easy, straightforward methodology akin to the experience of dealing with big automotive manufacturers that use Tier 1 suppliers in conjunction with smaller companies.
Mower’s sentiments were echoed by VP of Sales and Marketing over at Walker Component Group, Mark Rehder, who said that this strategic partnership is a win for both companies. Marrying FLXT’s brilliant technology expertise with Walker’s manufacturing muscle and supply chain prowess is a no-brainer. Rehder called the partnership a compelling platform for the markets and agreed with Mower that the partnership will accelerate negotiations with many current/future clients.
This deal is a shrewd move for FLXT, who can now focus on design and engineering while also providing product consumption end points with the reassurance they need to do bigger deals, as primary assembly, logistical, and manufacturing roles shift over to Walker. Looks like the new partnership has FLXT on-track for large-scale roll out of many of their products within the year and investors will indeed be keen to see the ensuing traction that this new vehicle is capable of producing.
For more information on Flexpoint Sensor Systems, visit www.Flexpoint.com
DARA Biosciences, a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products, announced today that Haywood D. Cochrane Jr. has been appointed chairman of the DARA board of directors and Paul Richardson has been appointed as a new board member.
Mr. Cochrane has been serving as a member of DARA’s board since February 2008. He has accumulated more than 30 years of executive and senior management experience in the healthcare industry. This experience includes senior vice president and chief operating officer positions at Roche Biomedical Laboratories, as well as serving as president and chief financial officer of Allied Clinical Laboratories and executive vice president and chief financial officer of Laboratory Corporation of America. Mr. Cochrane attended the University of North Carolina at Chapel Hill where he earned an A.B. degree in political science and was a Morehead Scholar.
“Haywood brings our board extensive executive and senior management experience in the healthcare industry and extraordinary abilities as a communicator and board facilitator. His relevant business expertise and leadership experience acquired through serving as vice chairman and chairman of the boards of directors of other healthcare-related companies make Haywood an outstanding choice to serve as the chairman of the board for DARA,” said David J. Drutz, M.D., DARA’s chief executive officer.
Mr. Richardson has an impressive background featuring over 30 years of senior executive experience in the bio-pharmaceutical industry. Throughout his career, Mr. Richardson has developed extensive, far-reaching experience in global product commercialization and development. Mr. Richardson possesses extensive strategic, managerial, and commercial skills that DARA can effectively leverage to grow in the future. Most recently, Mr. Richardson served as the President for Pfizer’s North American Specialty Business. Overall, Mr. Richardson’s expansive skill set strengthens DARA’s board by providing additional expertise in global commercial and development strategy.
Dr. Drutz concluded, “We are very grateful to have a board of directors with the experience, knowledge, and expertise necessary to support DARA in its ongoing efforts to become a preeminent oncology and oncology supportive care company.”
For further information, visit www.darabio.com
Today's Top 3
Jet-Life Penny Stocks
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) to Provide 2013 Business Outlook on March 6, 2013
- Bergamo Acquisition Corp. (BGMO) Provides Authenticated Documentation to Confirm Bank Deposits
- Consorteum Holdings, Inc. (CSRH) Reaches Funding Agreement With Private Equity Group
- Cardium Therapeutics, Inc. (CXM) Announces Presentation at The 2013 Cell & Gene Therapy Forum
- Duma Energy Corp. (DUMA) Receives 1.1 Billion Barrel P10 Estimate for Namibia Concession
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- HII Technologies, Inc. (HIIT) Announces Engagement of QualityStocks Investor Relations Services
- International Stem Cell Corp. (ISCO) Strengthens Intellectual Property Portfolio
- Loans4Less.com, Inc. (LFLS) Engages CPA Firm to Audit Financials
- Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products Starts Mfg. 3 New Products
- Rainbow Coral Corp. (RBCC) Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion Drug Delivery Market
- The Guitammer Company Inc. (GTMM) Joins Nationwide, North America's Largest Buying and Marketing Organization
- Viaspace, Inc. (VSPC) 25 Acres of Giant King Grass Shipped and Growing in St. Croix
- Viscount Systems, Inc. (VSYS) Freedom Installed at Additional BC Government Sites
- VistaGen Therapeutics, Inc. (VSTA) Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium